Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
So far, the only COVID-19 vaccines authorized for use need to be kept frozen. But there are many places in the world that can’t support a cold supply chain.
A new strain of the SARS-CoV-2 virus that causes COVID-19 appears to be spreading fast in the UK. This probably isn’t a big problem, but the data isn’t in yet.
COVID-19 vaccines have very specific storage requirements that make shipping a difficult task. Two ideas – fulfillment centers and cross-docking – could help overcome some distribution challenges.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
The side effects of new SARS-CoV-2 vaccines are a result of immune system activation. While uncomfortable, they are both normal and expected. They are a sign that the vaccine is working.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
Moderna’s shot is far easier to store and distribute than Pfizer’s. But there are concerns neither vaccine performs particularly well for older people.
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here’s where we stand on vaccine development, including positive results from Pfizer’s trial.
Early analysis suggests this vaccine has an efficacy of over 90%. So if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one would get sick.
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute